Summary
Methotrexate (MTX) was coupled to an IgM monoclonal antibody specific for stage-specific embryonic antigen-1 (SSEA-1), and the resulting immunoconjugate (MTX-anti-SSEA-1) was used for in vivo drug targeting in mice bearing MH-15 teratocarcinoma. Immunoconjugates having an average of 65 mol MTX/mol antibody retained full antigen-binding capacity. Mice bearing well-established tumors (approx. 1 g) were treated i.v. using the immunoconjugate. MTX-anti-SSEA-1 at 15 mg/kg of drug had significant antitumor activity with no significant systemic toxicity. Neither an irrelevant isotype-matched conjugate, MTX-MOPC-104E, prepared from the MOPC 104E myeloma protein, nor free MTX injected alone or with either antibody had any signficant antitumor effect. These results indicate that IgMs can be effective drug carriers for tumor targeting in spite of their high molecular mass, and that antigens that are selectively accessible in tumors, even though present in normal tissues, can be suitable targets for in vivo chemoimmunotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ballou B, Levine G, Hakala TR, Solter D (1979) Tumor location detected with radioactively labeled monoclonal antibody and external scintigraphy. Science 206:844
Ballou B, Jaffe R, Tylor RJ, Solter D, Hakala TR (1984) Tumor radioimmunolocation: differential antibody retention by antigenic normal tissue and tumor. J Immunol 132:2111
Ballou B, Reiland JM, Levine G, Taylor RJ, Shen WC, Ryser HJP, Solter D, Hakala TR (1986) Tumor location and drug targeting using a monoclonal antibody (anti-SSEA-1) and antigen-binding fragments. J Surg Oncol 31:1
Fox N, Shevinsky L, Knowles BB, Solter D, Damjanov I (1982) Distribution of murine stage-specific embryonic antigen in kidney of three rodent species. Exp Cell Res 140:331
Fox N, Damjanov I, Knowles BB, Solter D (1983) Immunohistochemical localization of the mouse stage-specific embryonic antigen-1 in human tissues and tumors. Cancer Res 43:663
Garnett MC, Baldwin RW (1986) An improved synthesis of a methotrexate-albumin-791T/36 monoclonal antibody conjugate cytotoxic to human osteogenic sarcoma cell lines. Cancer Res 46:2487
Garnett MC, Embleton MJ, Jacobs E, Baldwin RW (1983) Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vivo. Int J Cancer 31:661
Geran RI, Greenberg NH, MacDonald NM (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3(2):15
Ghose T, Blair AH (1987) The design of cytotoxic agent-antibody conjugates. In: Bruck SD (ed) Critical reviews in therapeutic drug carrier systems, vol 3 (4): 263, CRC Press, Inc. Boca Raton, Florida
Kulkarni PN, Blair AH, Ghose T (1981) Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. Cancer Res 41:2700
Levine G, Ballou B, Reiland J, Solter D, Gumerman L, Hakala TR (1980) Localization of I-131-labeled tumor-specific antibody in the tumor-bearing BALB/c mouse. J Nucl Med 21:570
Liebert M, Ballou B, Taylor RJ, Reiland JM, Hakala TR (1985) A method of membrane preparation for immunoassay. J Immunol Methods 85:97
Mathé G, Loc TB, Bernard J (1958) Essai sur la leucemie L1210 de la souris d'une combination par diazotazion d'amethopterine et de gamma-globulines de hamster porteurs de cette leucemie par heterogreffe. CR Hebd Séances Acad Sci 246:1626
Persiani S, Ballou BT, Shen WC, Hakala TR (1988) Biodistribution and activity of methotrexate-monoclonal anti-SSEA-1 in tumor-bearing mice. Fed Am Socs Exp Biol J 2:A815
Reintgen DS, Shimizu K, Coleman E, Briner W, Kitzmiller J, Eisenbarth G, Seigler HF (1983) Immunodiagnosis of tumors in vivo using radiolabelled monoclonal antibody A2B5. J Surg Oncol 23:205
Saunders GC (1979) The art of solid-phase enzyme immunoassay including selected protocols. In: Nakamura RM, Dito WR, Tucker ES, III, (eds) Immunoassay in the clinical laboratory: proceedings of the first annual conference on immunoassays in the clinical laboratory, La Jolla, California. Liss, New York
Saunders GC, Clinard EH, Bartlett ML, Petersen PM, Sanders WM, Payne RJ, Martinez E (1978) Serologic tests system development. Los Alamos Scientific Laboratory of the University of California Progress Report LA-7078-PR: 1
Shen WC, Ballou B, Ryser HJP, Hakala TR (1986) Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells. Cancer Res 46:3912
Smyth MJ, Pietersz GA, McKenzie FC (1987) The mode of action of methotrexate-monoclonal antibody conjugates. Immunol Cell Biol 65 (2):189
Solter D, Knowles BB (1978) Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc Natl Acad Sci USA 75:5565
Uadia P, Blair H, Ghose T (1983) Uptake of methotrexate linked to an anti-EL4-lymphoma antibody by EL4 cells. Cancer Immunol Immunother 16:127
Vessella R, Chiou R, Elson M,, Nowak J, Rittenhouse H, Stroup S, Alvarez V, Palme D, Shaffer R, Lange P (1986) 111-In imaging of renal cell carcinoma (RCC) xenograft and 131-I primate dosimetry with monoclonal antibody (Mab) A6H. Proc Am Assoc Cancer Res 27:337
Author information
Authors and Affiliations
Additional information
Supported by intramural research funds from the Veteran's Administration, Pittsburgh Cancer Institute, and NIH grants CA34798 and CA 14551
Rights and permissions
About this article
Cite this article
Persiani, S., Ballou, B., Shen, WC. et al. In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen-1, on MH-15 mouse teratocarcinoma. Cancer Immunol Immunother 29, 167–170 (1989). https://doi.org/10.1007/BF00199991
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199991